# Cholesterol Lowering With EVOLocumab to Prevent Cardiac Allograft Vasculopathy in De-novo Heart Transplant Recipients

> **NCT03734211** · PHASE3 · COMPLETED · sponsor: **Lars Gullestad** · enrollment: 130 (actual)

## Conditions studied

- Cardiac Allograft Vasculopathy

## Interventions

- **DRUG:** Evolocumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03734211
- **Lead sponsor:** Lars Gullestad
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-10
- **Primary completion:** 2023-05-20
- **Final completion:** 2023-05-20
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2023-11-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03734211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03734211, "Cholesterol Lowering With EVOLocumab to Prevent Cardiac Allograft Vasculopathy in De-novo Heart Transplant Recipients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03734211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*